What Ambio Life Sciences does

Ambio Life Sciences is a privately held, vertically integrated medical clinic operator that delivers integrative ibogaine treatment programs for addiction recovery, traumatic brain injury (TBI), chronic neurological conditions, and personal optimization. Founded by Jonathan Dickinson (CEO), Trevor Millar (COO), and José Inzunza (CMO) — three clinicians with over 50 years of combined ibogaine expertise — the company runs six medical-grade treatment homes in Baja California, Mexico and one physician-led clinic in Malta, making it the only transcontinental ibogaine provider. As of 2025, Ambio has safely completed over 4,000 treatments with no reported adverse events and treats more than 50 patients per month.

The company offers three core fee-for-service programs: the Foundational Program (5-day personal transformation), the Detoxification Program (7–30 days for substance cessation, including opioids/fentanyl and alcohol), and the Neuroregenerative Program (4-day onsite plus 3-month microdosing for TBI, MS, Parkinson's, and neuropathic pain). Treatments rely on ibogaine, a plant-derived alkaloid extracted from Tabernanthe iboga, sourced through the world's first Nagoya-Protocol-compliant supply chain (IBEX011, produced with Terragnosis Inc. and Filament Health from Gabonese A2E Association farms). Ambio's proprietary, patent-pending safety protocol — including cardiac monitoring, magnesium supplementation, individualized dosing, and pre-treatment EKG/blood screening — underpins clinical credibility and was co-authored as industry Clinical Guidelines in 2015.

Ambio generates revenue through one-time program fees ranging from $7,350 to $30,000 USD (plus a $1,000 veterans/first-responders discount), with deposits and wire transfers as the primary payment mechanism. The go-to-market motion is direct, sales-led intake via medical application and advisor consultation; demand is reflected in waitlists of several months to a year. Marketing is anchored by earned media (New York Times Magazine, Wall Street Journal, L.A. Times, Huberman Lab, Netflix's 'In Waves and War' 2025 documentary) and Stanford University-co-authored research published in Nature Medicine. Patient mix spans veterans (including U.S. Navy SEALs), elite athletes (NFL, UFC), high-performing individuals, and chronic neurological patients, with grant funding support from VETS and 343 Fund for qualifying veterans.

Name

Ambio Life Sciences

Legal name

Ambio Life Sciences

Website

https://ambio.life

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Ambio Life Sciences operates a vertically integrated medical clinic business delivering physician-supervised ibogaine therapy for addiction, TBI, and neurodegenerative conditions across seven treatment homes in Mexico and Malta. It serves veterans, elite athletes, and high-performing individuals with programs priced from $7,350 to $30,000 USD.

Ownership category

akta.pro rank

Product category

Addiction Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Residential Substance Use Rehabilitation (Inpatient Rehab) (HLAFACAE)

Keywords

• Ibogaine treatment
• Addiction recovery
• Wellness clinic services
• Detoxification programs
• Neurological therapy

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D

Revenue model

1. Ibogaine Treatment Programs: Ambio generates revenue through fee-for-service treatment programs. Patients pay for one of three programs (Foundational, Detoxification, or Neuroregenerative) ranging from $7,350 to $30,000 USD depending on program type and duration. A deposit is required to secure a place. The primary form of payment is wire transfer. No credit card or cash payments are accepted.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Ambio Life Sciences operates physician-led residential ibogaine treatment clinics in Baja California, Mexico and Malta, delivering fee-for-service integrative ibogaine therapy programs (Foundational, Detoxification, and Neuroregenerative) for addiction interruption, traumatic brain injury, neurodegenerative conditions, and personal optimization. Treatment is supported by 24/7 medical staffing, a patent-pending cardiac protection and metabolism facilitation safety protocol, and a proprietary Nagoya-Protocol-compliant GMP iboga extract (IBEX011). Patients access care through a direct online application and intake process, paying program fees ranging from $7,350 to $30,000 USD.

Product overview

Ambio Life Sciences offers a platform of integrative ibogaine treatment programs delivered at medical-grade clinics in Mexico and Malta. The core offerings consist of three distinct programs: the Foundational Program (5-day personal transformation), the Detoxification Program (7-30 day substance cessation), and the Neuroregenerative Program (4-day onsite plus 3-month microdosing for neurological conditions). These programs are supported by a patient portal for intake and preparation, and an online shop for integration products. All treatments utilize ibogaine, a plant-derived medicinal alkaloid, administered under comprehensive medical oversight in physician-led facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Foundational Program A 5-day physician-led ibogaine treatment program focused on personal transformation, mental clarity, emotional resilience, and relief from depression, anxiety, complex trauma, and burnout. Includes comprehensive medical oversight, ibogaine flood dose treatment, and integration support. Available in Mexico (USD) and Malta (EUR).
• Detoxification Program A 7–30 day program designed to support safe, effective substance cessation for opioid use disorder (including fentanyl, heroin, Suboxone, methadone), alcohol dependency, and other substance use disorders. Provides ibogaine treatment to interrupt dependency at a biochemical and behavioral level, with restoration of agency, clarity, and self-direction. Available in Mexico.
• Neuroregenerative Program A 4-day onsite ibogaine treatment plus 3-month microdosing program targeting long-term neurological healing. Designed for chronic neurological conditions such as traumatic brain injury (TBI), Multiple Sclerosis (MS), and Parkinson's disease. Includes optional microdosing protocols, coaching, and integration resources.
• Ambio Online Shop E-commerce platform offering Ambio-branded supplements and integration support items for patients completing ibogaine treatment programs.

Quantifiable outcome

• Over 4,000 safe treatments completed; zero adverse events in 2022 and on track for zero in 2023 with ~30% treatment volume increase
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Terragnosis Inc.coreTechnology or Integration · 20 May 2024Terragnosis Inc., a Canadian drug development company, developed IBEX011 — the first GMP iboga extract compliant with the Nagoya Protocol. Jonathan Dickinson serves as CEO of both Terragnosis and Ambio, making this an affiliated entity. Terragnosis supplies Ambio with its iboga extract, which is at least 30% stronger by weight than single-molecule ibogaine. The extract contains all naturally occurring alkaloids from Tabernanthe iboga root bark sourced from Gabon.
• Filament HealthsupportingTechnology or Integration · 20 May 2024Filament Health is Ambio's laboratory partner in western Canada responsible for processing the iboga supplied by the A2E Association into a purified total alkaloid (PTA) extract (IBEX011). They are a key part of the supply chain for Ambio's Nagoya-compliant ibogaine product.
• Blessings of the Forest (BoTF)coreStrategic or Co-development Partner · 20 May 2024Blessings of the Forest is a non-profit dedicated to the preservation and development of Gabonese cultural and natural heritage. BoTF architected and implemented Gabon's Nagoya Protocol strategy and financed 20 iboga farms including the A2E Association. BoTF facilitated the first legal iboga export from Gabon in decades and represents Ambio's commitment to equitable benefit sharing with traditional knowledge holders from the Bwiti tradition.
• Stanford UniversitycoreStrategic or Co-development Partner · 1 January 2024Stanford University researchers, led by Dr. Nolan Williams, conducted a clinical trial on ibogaine treatment for Special Ops military veterans with traumatic brain injury. Results were published in Nature Medicine. The study showed ibogaine effectively treats TBI and may 'turn back the biological age' of the brain by an average of 1.4 years. Ambio co-authored and supported this research.
• A2E Association (Ebyeng, Gabon)coreStrategic or Co-development Partner · 20 July 2023The A2E Association in Ebyeng is a Fang community in northeastern Gabon with the most mature iboga farm in the world. Ambio (via Terragnosis) sources its iboga root bark from this community, making it the first legal export of iboga from Gabon since exports were halted in 2016. This partnership is central to Ambio's Nagoya Protocol compliance and ethical sourcing commitment.
• Veterans Exploring Treatment Solutions (VETS)supportingGTM or Marketing PartnerVETS is a grant organization that may assist veterans and service members with funding support for ibogaine treatment at Ambio. Listed alongside the 343 Fund as a potential additional support resource for those who qualify.
• 343 FundsupportingGTM or Marketing PartnerA grant organization that may assist veterans with additional financial support for ibogaine treatment at Ambio, alongside VETS.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable in psychedelic therapeutic thesis, clinical development focus, and broad pipeline approach.
• Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Comparable to Ambio in psychedelic therapeutic positioning, regulatory navigation, and clinical evidence emphasis.
• MindMed: Neurology-focused psychedelic medicine developer working on LSD, MDMA, and psilocybin. Comparable to Ambio in mental-health/neurology psychedelic pipeline, though focused on drug development rather than clinic operations.

Others

• Filament Health: Botanical psychedelic drug developer and Ambio's GMP laboratory partner producing IBEX011 in western Canada. Comparable in psychedelic API development, GMP-grade botanical extraction, and clinical supply chain — though not a clinic operator.

Direct peers

• Field Trip Health: Operated psychedelic-assisted therapy clinics (ketamine, psilocybin) for mental health across North America and Europe. Directly comparable to Ambio in clinic-based psychedelic therapy delivery, premium pricing model, and physician-supervised protocols.
• The Holistic Sanctuary: Mexico-based residential addiction treatment center using plant medicines and Ibogaine derivatives. Comparable to Ambio in service model (boutique residential treatment), therapy stack, and high-acuity patient segment.
• Clear Sky Recovery: Cancun-based ibogaine treatment clinic offering residential addiction recovery programs. Directly comparable to Ambio in therapeutic modality, patient profile (opioid/alcohol dependency), and Mexican operating model.

Broad incumbents

• Recovery Centers of America: Multi-state US operator of inpatient and outpatient addiction treatment centers. Comparable in residential substance use rehabilitation positioning, patient acuity, and multi-facility operating model.
• American Addiction Centers: Large network of residential and outpatient addiction treatment facilities across the US. Comparable to Ambio in addiction treatment focus and residential model, but operates at much larger scale using conventional (non-psychedelic) approaches.
• Hazelden Betty Ford Foundation: One of the largest US addiction treatment providers with residential, outpatient, and recovery services. Comparable in residential substance use treatment delivery, though conventional rather than psychedelic-assisted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ambiolifesciences
• Facebookfacebook.com/AmbioLifeSciences
• LinkedInlinkedin.com/company/ambio-life-sciences
• Instagraminstagram.com/ambiolifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambio Life Sciences